We came across a bullish thesis on Merck & Co., Inc. (MRK) on Value Investing Subreddit Page by CompanyCharts. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc. (MRK)’s ...

The companies will evaluate the combination of ATG-022 and MSD's anti-PD-1 therapy, KEYTRUDA, in patients with advanced solid ...

Those two descriptions definitely apply to the healthcare sector. People need healthcare products and services regardless of ...

Merck and Antengene joined forces to test ATG-022 with KEYTRUDA®, a combo that could strengthen Merck’s cancer-fighting ...

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

The company bought the rights to an experimental cancer drug for $1.3 billion, plus potential milestone payments of $4.8 ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

Chris Toomey, Morgan Stanley managing director of private wealth, said in a latest program on CNBC that he is not bullish on stocks yet and plans to “stay defensive” until a few key issues are ...

A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...

To be fair, Merck represents one of the stalwarts of healthcare, historically making it one of the more reliable names in the ...